Site content: Global

Press Release

CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic strategy supporting patient care in HR+/HER2- metastatic breast cancer

STIC CTC trial data published this November 2023 in the Journal of Clinical Oncology (JCO) demonstrate that CTC-guided treatment decision confers superior survival benefits in a subgroup...

New STIC trial data shows longer overall survival for therapy selection based on CELLSEARCH® CTC count in patients with metastatic breast cancer

Integration of CTC (Circulating Tumor Cell) enumeration* to decide between endocrine therapy and chemotherapy may lead to improved clinical outcomes and quality of life for patients with...

Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early

Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the...

Menarini Silicon Biosystems’s CELLSEARCH® CMMC and HER2-CTC Liquid Biopsy Tests obtain Reimbursement Codes with Preliminary Pricing Determination

These new codes are required to access Medicare/Medicaid insurance reimbursement for novel CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) and HER2 Circulating Tumor Cell (CTC-HER2)...

Menarini Silicon Biosystems launches new breakthrough DEPArray™ PLUS image-based cell sorter to isolate rare cells with single cell precision

DEPArray™ PLUS – the new automated and versatile platform to investigate pre-selected rare cell populations from various samples with 100% purity, now enhanced with 9...

Menarini Silicon Biosystems announces launch of CellMag™ product line offering affordable Gold Standard Circulating Tumor Cells capture

CELLMAG – a cost effective, manual and simple approach for the enrichment and staining of extremely rare cells from blood   BOLOGNA, Italy and HUNTINGDON VALLEY,...

New ASCO Studies Offer Evidence for Use of Circulating Tumor Cells as a Prognostic Biomarker for Advanced Prostate and Breast Cancer

Results from prospective trials show a "clear prognostic value" for CTC counts   BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., June 9, 2020 /PRNewswire/ -- Menarini...

Menarini Silicon Biosystems to Host ESMO Symposium on Clinical Importance of Circulating Tumor Cells

World-renowned faculty will present current evidence and potential clinical applications of CTCs for advanced breast and prostate cancer   Bologna, Italy and Huntingdon...

New Studies Using CELLSEARCH Circulating Tumor Cell Test to be Featured at San Antonio Breast Cancer Symposium

Research Adds to Growing Evidence of Clinical Utility of CTCs for the management of Metastatic Breast Cancer Patients Bologna, Italy and Huntingdon Valley, Pa., NOVEMBER 29, 2018 --...
12